Multiple named pharmacy partners have documented FDA enforcement actions or state board proceedings, several of which remain unresolved
I think a lot of companies we're going to see maybe shifting away from this custom approach because they are afraid that the FDA could come in any day and shut them down and say you can't do this anymore. George Ball, Indiana University associate professor of operations and decision technologies, has a different take on the situation
Conclusion Retatrutide and Mounjaro are both impressive for weight loss and blood sugar control

CrossRef PrevotellaDerived Butyrate Inhibits CD8+ TCell Glycolysis via AKT/mTOR Signalling to Alleviate MASH Feixiang Xiong, Fengna Yan, Yuyong Jiang, Xiaomin Ji, Tong Wu, Yang Zhou, Xuejie Zhang, Dandan Chen, Yixin Hou Liver International .2026;[Epub] CrossRef CT-assessed abdominal visceral adiposity and MASLD: a sex-stratified cross-sectional analysis Linying Xu, Ting Chen, Yitian Xie, Xueyu Xiang, Yupeng Liu, Chongyong Xu, Shuran Wang Frontiers in Nutrition .2026;[Epub] CrossRef MetALD at the crossroads of metabolic and alcohol-related liver disease Gustavo Ayares, Luis Antonio Daz, Juan Pablo Arab, Marco Arrese Trends in Endocrinology & Metabolism .2026;[Epub] CrossRef Placebo-associated changes in MRI-PDFF and metabolic parameters in MASLD patients from phase Ib/IIa clinical trials: implications for early-phase trial design and translational endpoint interpretation Mengdi Lu, Hong Zhang, Xiaoxue Zhu, Jia Xu, Lin Xiang, Yue Hu, Jixuan Sun, Jiajia Mai, Yanhua Ding Frontiers in Pharmacology .2026;[Epub] CrossRef Aging-related skeletal muscle loss on the incidence of chronic kidney disease in patients with metabolic dysfunction-associated steatotic liver disease Aryoung Kim, Danbee Kang, Sung Chul Choi, Dong Hyun Sinn, Hye Ryoun Jang, Geum-Youn Gwak The Journal of nutrition, health and aging .2026

The study explores various clinical forms and pathogenic mechanisms behind PPH while discussing diagnostic tools like continuous glucose monitoring or mixed meal tolerance tests
4jl), intestinal FXR inhibition (Fig